Search
Now showing items 1-10 of 50
SARS-CoV-2 and Multiple Sclerosis: Not all immune depleting DMTs are equal or bad.
(Wiley Online, 2020-05-08)
A major concern during the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic1 is the use of immunosuppressive therapies for the treatment of multiple sclerosis (MS) due to an increased risk of ...
Reversal of behavioural phenotype by the cannabinoid-like compound VSN16R in fragile X syndrome mice.
(2021-07-01)
Fragile X Syndrome is the most common inherited intellectual disability and mono-genetic cause of autism spectrum disorder. It is a neurodevelopmental condition occurring due to a CGG trinucleotide expansion in the FMR1 ...
Cladribine Personalised Dosing to Treat Active Multiple Sclerosis - Follow-up in 250 patients
(2021-06)
This is the accepted manuscript of an article published online:
1. ACTRIMS Forum 2021 – Poster Presentations. Multiple Sclerosis Journal. 2021;27(1_suppl):15-122. doi:10.1177/13524585211015908
Highly effective disease-modifying treatment as initial MS therapy.
(2021-06-01)
PURPOSE OF REVIEW: Using highly effective (HE) compounds right from the beginning of disease-modifying immunotherapy (DMT) in people with multiple sclerosis (pwMS) has gained popularity among clinicians and pwMS alike. We ...
